Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells

详细信息    查看全文

• 作者：Yehua Shen ; Yan Pan ; Litao Xu ; Lianyu Chen ; Luming Liu ; Hao Chen…
• 关键词：Pancreatic cancer ; Gemcitabine resistance ; RNA ; seq ; Differential genes and microRNAs ; MicroRNA ; mRNA network
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：36
• 期：6
• 页码：4525-4534
• 全文大小：3,772 KB
• 参考文献：1.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-0.PubMed View Article
  2.Warshaw AL, Fernandez-del CC. Pancreatic carcinoma. N Engl J Med. 1992;326:455-5.PubMed View Article
  3.Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226:248-7.PubMed Central PubMed View Article
  4.Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol. 2001;96:2609-5.PubMed View Article
  5.Stefanska B, Arciemiuk M, Bontemps-Gracz MM, Dzieduszycka M, Kupiec A, Martelli S, et al. Synthesis and biological evaluation of 2,7-Dihydro-3H-dibenzo[de, h]cinnoline-3,7-dione derivatives, a novel group of anticancer agents active on a multidrug resistant cell line. Bioorg Med Chem. 2003;11:561-2.PubMed View Article
  6.Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2-2-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000-.PubMed
  7.Saif MW. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer: are we there yet? JOP. 2010;11:288-.PubMed
  8.Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004;23:1539-8.PubMed View Article
  9.Giovannetti E, Del TM, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928-5.PubMed View Article
  10.Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery. 2004;135:555-2.PubMed View Article
  11.Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. SiRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg. 2004;198:953-.PubMed View Article
  12.Liau SS, Ashley SW, Whang EE. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10:1254-2.PubMed View Article
  13.Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, Harada T, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007;67:6786-5.PubMed View Article
  14.Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 2008;14:1284-.PubMed View Article
  15.Zhao YP, Chen G, Feng B, Zhang TP, Ma EL, Wu YD. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer. Chin Med J (Engl). 2007;120:1743-2.
  16.Lee KH, Galloway JF, Park J, Dvoracek CM, Dallas M, Konstantopoulos K, et al. Quantitative molecular profiling of biomarkers for pancreatic cancer with functionalized quantum dots. Nanomedicine. 2012;8:1043-1.PubMed Central PubMed View Article
  17.Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science. 2003;301:336-.PubMed View Article
  18.Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010;17:523-1.PubMed View Article
  19.Paik WH, Kim HR, Park JK, Song BJ, Lee SH, Hwang JH. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res. 2013;33:1473-1.PubMed
  20.Mittal A, Chitkara D, Behrman SW, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 2014;35:7077-7.PubMed View Article
  21.Giovannetti E, Funel N, Peters GJ, Del CM, Erozenci LA, Vasile E, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528-8.PubMed View Article
  22.Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, et al. MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 2013;43:1066-2.PubMed
  23.Li Y, VandenBoom TN, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-2.PubMed Central PubMed View Article
  24.Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, et al. MicroRNA expression as a predictive marke
• 作者单位：Yehua Shen (1) (2)
  Yan Pan (1) (2)
  Litao Xu (1) (2)
  Lianyu Chen (1) (2)
  Luming Liu (1) (2)
  Hao Chen (1) (2)
  Zhen Chen (1) (2)
  Zhiqiang Meng (1) (2)
  
  1. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China
  2. Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong’An Road, Shanghai, 200032, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Pancreatic cancer is unresectable in over 80?% of patients owing to difficulty in early diagnosis. Chemotherapy is the most frequently adopted therapy for advanced pancreatic cancer. The development of drug resistance to gemcitabine (GEM), which is always used in standard chemotherapy, often results in therapeutic failure. However, the molecular mechanisms underlying the gemcitabine resistance remain unclear. Therefore, we sought to explore the microRNA-mRNA network that is associated with the development of gemcitabine resistance and to identify molecular targets for overcoming the gemcitabine resistance. By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50?% growth inhibition, 847.23?μM). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed, which included hub microRNAs, such as hsa-miR-643, hsa-miR-4644, hsa-miR-4650-5p, hsa-miR-4455, hsa-miR-1261, and hsa-miR-3676. The predicted targets of these hub microRNAs in the microRNA-mRNA network were also observed in the identified differential genes. As a result, a differential gene and microRNA expression pattern was constructed in gemcitabine-resistant pancreatic cancer cells. Therefore, these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.